Compare RVLV & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | GALT |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 297.0M |
| IPO Year | 2018 | 2008 |
| Metric | RVLV | GALT |
|---|---|---|
| Price | $21.17 | $3.76 |
| Analyst Decision | Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $30.85 | N/A |
| AVG Volume (30 Days) | ★ 716.8K | 248.5K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.64 | ★ 36.84 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,225,682,000.00 | N/A |
| Revenue This Year | $13.31 | N/A |
| Revenue Next Year | $9.03 | N/A |
| P/E Ratio | $46.52 | ★ N/A |
| Revenue Growth | ★ 8.48 | N/A |
| 52 Week Low | $17.35 | $2.03 |
| 52 Week High | $31.68 | $7.13 |
| Indicator | RVLV | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 54.69 |
| Support Level | $19.25 | $3.56 |
| Resistance Level | $22.11 | $4.30 |
| Average True Range (ATR) | 0.72 | 0.19 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 49.18 | 71.97 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.